-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Click on the blue text above to follow us.
In an "Perspective", Ravindra Gupta and Eric Topol discuss the efficacy of the COVID-19 vaccine in the context of breakthrough infections and the emergence of new variants
.
Although no vaccine can prevent all infections, few can achieve such a high level of protection as the two-dose messenger ribonucleic acid (mRNA) vaccine currently developed to combat SARS-CoV-2
.
In a large number of clinical trials (one of the largest trials ever), it was found that the COVID-19 mRNA vaccine has a high level of protection against symptomatic diseases
.
However, ongoing research shows that this protective effect will diminish over time, especially in the elderly and people with weakened immune functions
.
Recently, in response to the ever-increasing prevalence of breakthrough vaccine infections and new variants of SARS-CoV-2, studies have shown that the third booster dose can restore the effectiveness of the vaccine to more than 90%
.
In this regard, Gupta and Topol reviewed recent studies on the breakthrough infection of the COVID-19 vaccine and the efficacy of boosters in preventing SARS-CoV-2 variants (such as Delta)
.
The authors concluded that although boosters are important and may last for a while, non-pharmacological interventions, such as wearing masks and maintaining social distancing, not only help reduce COVID-19 cases, but also limit the emergence of evasion Opportunities for immune variants
.
Welcome to pay attention to Science's official public account.
Click "Read the original text" below to visit the English original text of this issue of Science.
In an "Perspective", Ravindra Gupta and Eric Topol discuss the efficacy of the COVID-19 vaccine in the context of breakthrough infections and the emergence of new variants
.
Although no vaccine can prevent all infections, few can achieve such a high level of protection as the two-dose messenger ribonucleic acid (mRNA) vaccine currently developed to combat SARS-CoV-2
.
In a large number of clinical trials (one of the largest trials ever), it was found that the COVID-19 mRNA vaccine has a high level of protection against symptomatic diseases
.
However, ongoing research shows that this protective effect will diminish over time, especially in the elderly and people with weakened immune functions
.
Recently, in response to the ever-increasing prevalence of breakthrough vaccine infections and new variants of SARS-CoV-2, studies have shown that the third booster dose can restore the effectiveness of the vaccine to more than 90%
.
In this regard, Gupta and Topol reviewed recent studies on the breakthrough infection of the COVID-19 vaccine and the efficacy of boosters in preventing SARS-CoV-2 variants (such as Delta)
.
The authors concluded that although boosters are important and may last for a while, non-pharmacological interventions, such as wearing masks and maintaining social distancing, not only help reduce COVID-19 cases, but also limit the emergence of evasion Opportunities for immune variants
.
Welcome to pay attention to Science's official public account.
Click "Read the original text" below to visit the English original text of this issue of Science.